Component information
No US or EU label exists for this exact combination, so information is shown for each component.
Use: Type 2 diabetes, modified-release (MR) renalcarematters.com, reviewed
Kidney dosing: Gliclazide (single-agent)Show full dosing details
- CrCl ≥60 mL/min
- Usual dosing. Modified-release (MR): 30 to 120 mg once daily at breakfast. Immediate-release 80 mg tablets: 40 to 80 mg/day to start, maximum 320 mg/day; doses above 160 mg/day are split before breakfast and dinner (SmPC).
- CrCl 30–59 mL/min
- Mild to moderate impairment: same regimen as normal kidney function with careful glucose monitoring (MR SmPC). Immediate-release: use caution above 160 mg/day and consider limiting the maximum dose as serum creatinine rises (IR SmPC). Start at the lowest dose (MR 30 mg or IR 40–80 mg) and titrate slowly; reduce if hypoglycemia occurs (KDIGO 2022, Figure 6).
- CrCl 15–29 mL/min
- Severe renal insufficiency: contraindicated; insulin is recommended (SmPC). Our mapping of 'severe' to CrCl <30 is a judgment. Off-label use below 30 is a specialist decision: lowest dose, close glucose monitoring.
- CrCl <15 mL/min (not on dialysis)
- Contraindicated (severe renal insufficiency; SmPC).
- Hemodialysis (intermittent)
- Contraindicated (severe renal insufficiency; SmPC). Dialysis does not remove gliclazide because it is highly protein-bound (SmPC 4.9).
- Peritoneal dialysis
- Contraindicated (severe renal insufficiency; SmPC).
- CRRT
- Not appropriate; contraindicated in severe renal insufficiency (SmPC). Use insulin.
- Dialyzable? No: dialysis is of no benefit in overdose because gliclazide is about 95% protein-bound (SmPC 4.9).
- Monitoring Glucose (fasting plasma glucose, glycated hemoglobin [HbA1c], self-monitoring). Hypoglycemia can be prolonged in severe kidney impairment and needs longer observation (SmPC 4.4). Reassess kidney function periodically. G6PD deficiency: sulfonylureas can cause hemolytic anemia; use with caution and consider a non-sulfonylurea alternative (SmPC 4.4).
From the Gliclazide monograph (renalcarematters.com, reviewed).
Use: Metformin Hydrochloride Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. US FDA label
Kidney dosing: Metformin (single-agent)Show full dosing details
- eGFR ≥60
- Usual dosing. Assess kidney function before starting and periodically (label).
- eGFR 30–59
- eGFR 45–59: usual dose; consider dose reduction if at high risk of lactic acidosis. eGFR 30–44: label advises not to start; if continuing, reduce to a maximum of 1,000 mg/day (KDIGO 2022; ADA-KDIGO 2022). Recheck eGFR every 3 to 6 months.
- eGFR 15–29
- Contraindicated (label). Stop if eGFR falls below 30.
- eGFR <15 (not on dialysis)
- Contraindicated (label).
- Hemodialysis (intermittent)
- Contraindicated (eGFR <30 per label).
- Peritoneal dialysis
- Contraindicated (eGFR <30 per label).
- CRRT
- Not appropriate; contraindicated in severe kidney impairment (label).
- Dialyzable? Yes: dialyzable with clearance up to 170 mL/min under good hemodynamic conditions; hemodialysis may help remove drug in suspected overdose (label).
- Monitoring eGFR before starting and at least periodically; more often in older adults. Stop before or at the time of iodinated contrast in at-risk patients per label. Hold temporarily during acute illness with dehydration, sepsis, hypoxia or acute heart failure, during procedures with restricted food or fluid intake, and for acute kidney injury; restart when eating and kidney function is stable (label 5.1).
From the Metformin monograph (renalcarematters.com, reviewed).
Use: Monotherapy and Combination Therapy ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies (14) ] . US FDA label
Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney dosing for each component (single-agent) is shown under Component information.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Film-coated tablet: 500 mg/80 mg/15 mg
Registered products in the Philippines
1 product registered with the Food and Drug Administration (FDA) Philippines list Gliclazide + Metformin + Pioglitazone as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
TrizericMetformin hydrochloride + Gliclazide + Pioglitazone (as hydrochloride) | 500 mg/80 mg/15 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Ajanta Pharma LimitedIndia | Ajanta Pharma Philippines, Inc.Importer: Ajanta Pharma Philippines Inc.. | DR-XY47892 | Apr 4, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .
